How to Help Your Patients Save Money on Phyrago: A Provider's Guide to Savings Programs

The financial burden of specialty oncology medications is one of the most significant barriers to treatment adherence in patients with Philadelphia chromosome-positive (Ph+) leukemia. Phyrago (dasatinib), like all specialty oncology TKIs, carries a high list price that is inaccessible without insurance coverage or financial assistance programs. As a prescribing oncologist or hematologist, your guidance on available savings programs can be the difference between a patient starting therapy and abandoning it at the pharmacy.

This guide provides a comprehensive overview of financial assistance options available for Phyrago patients in 2026, organized by insurance status, along with practical guidance on enrollment.

The Financial Landscape for Phyrago in 2026

Phyrago is a specialty tier drug with a high list price. Comparable brand-name dasatinib products (Sprycel) have list prices exceeding $9,000 for 60 tablets at 20 mg, with higher-dose regimens (100 mg or 140 mg daily) costing substantially more per 30-day supply. Specialty tier cost-sharing can leave commercially insured patients responsible for 20–33% of this cost without assistance programs.

Understanding the available programs by insurance type is critical for your practice to effectively support patients:

For Commercially Insured Patients: Cycle Vita Copay Assistance

The Cycle Vita program, operated by Cycle Pharmaceuticals in partnership with Handa Therapeutics, is the primary financial assistance vehicle for commercially insured Phyrago patients. Key features of the program:

• Eligible patients may pay as little as $0 per month. Eligibility criteria apply; designed for commercially insured patients only.

• Free starter supply: Provides initial medication while benefit verification and prior authorization are being processed. Eliminates the treatment gap between prescribing and coverage approval.

• Benefit verification and PA support: Reduces administrative burden on your practice staff.

• Clinical education support: Adherence counseling and product information for patients.

Enrollment: Contact 888-360-8482 or have patients/staff enroll via phyrago.com/hcp/enroll/. Patients who do not want full hub support may still be eligible for copay assistance alone.

For Medicare Patients: Independent Foundation Grants

Manufacturer copay cards are excluded under federal anti-kickback statutes for patients with Medicare or Medicaid. However, several independent foundations provide meaningful financial assistance for Medicare patients with CML and Ph+ ALL:

• Leukemia & Lymphoma Society (LLS) Co-Pay Assistance Program: Provides direct co-pay assistance for patients with leukemia on Medicare. Apply at lls.org/financial-assistance. Eligibility is income-based; funds are limited and vary by year.

• Patient Advocate Foundation Co-Pay Relief: Offers financial assistance to patients who are insured but cannot afford their co-pay, deductible, or cost-sharing. Apply at patientadvocate.org.

• HealthWell Foundation: Operates disease-specific assistance funds including for CML. Apply at healthwellfoundation.org.

• Good Days / CancerCare: Provide co-pay assistance for cancer patients regardless of Medicare status.

Also note: As of 2025, Medicare Part D capped out-of-pocket prescription costs at $2,000 per year. For patients who reach this cap, the plan covers 100% of remaining drug costs for the rest of the plan year — a significant benefit for expensive specialty drugs like Phyrago.

For Uninsured or Underinsured Patients: Patient Assistance Program (PAP)

For patients without insurance or with insufficient coverage, a patient assistance program (PAP) is the primary resource. PAPs provide medication at little or no cost based on income criteria. Contact the Cycle Vita program at 888-360-8482 to inquire about PAP eligibility for Phyrago. Handa Therapeutics sponsors PAP access through this channel.

Insurance Prior Authorization and Step Therapy Appeals

Beyond direct financial assistance, prior authorization denials and step therapy requirements can delay or prevent access to Phyrago even for insured patients. Key documentation to include in PA submissions and appeals:

• Confirmed Ph+ CML or Ph+ ALL diagnosis with cytogenetic or molecular documentation

• Concurrent PPI or H2RA use (required to justify Phyrago over generic dasatinib for step therapy override)

• Published pharmacokinetic data showing 40–60% dasatinib exposure reduction with PPIs (cite Phyrago prescribing information)

• For appeals: NCCN guideline support (Phyrago is listed in NCCN CML v.1.2026 guidelines)

Practical Implementation: How to Set Up Your Practice

Consider implementing these practice-level processes to streamline Phyrago financial assistance for your patients:

1. Designate a staff member (financial counselor or patient care coordinator) to manage specialty medication access for all your oncology patients

2. Build Cycle Vita enrollment into the new Phyrago prescription workflow — submit the enrollment form at the same time you write the prescription

3. Have the Cycle Vita phone number (888-360-8482) and enrollment form available in your prescribing workflow

4. For Medicare patients, maintain a list of active foundation grants and check funding availability quarterly, as these programs open and close enrollment throughout the year

To help your patients navigate pharmacy availability alongside financial assistance, visit medfinder.com/providers. See also How to help your patients find Phyrago in stock for the full access pathway guide.